Tumor genome sequencing has demonstrated that mutagenesis from APOBEC3A is widespread throughout human cancers (Alexandrov et al, 2020; Petljak and Alexandrov, 2016), however the mechanisms that enable the dysregulated activity of APOBEC3A in cancer remain elusive. This evidence concerns the gene APOBEC3A and cancer.